CELG RT — Bristol-Myers Squibb Co Cashflow Statement
0.000.00%
Last trade - 00:00- $97.48bn
- $135.47bn
- $48.30bn
- 97
- 87
- 40
- 88
Annual cashflow statement for Bristol-Myers Squibb Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8,995 | 7,014 | 6,345 | 8,040 | -8,933 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 10,701 | 1,153 | 1,412 | 1,262 | 15,802 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 983 | -1,253 | -2,229 | -1,914 | 810 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 14,052 | 16,207 | 13,066 | 13,860 | 15,190 |
| Capital Expenditures | -753 | -973 | -1,118 | -1,209 | -1,248 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -10,106 | 435 | 56 | -1,086 | -20,104 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -10,859 | -538 | -1,062 | -2,295 | -21,352 |
| Financing Cash Flow Items | 542 | 641 | 984 | 27 | -106 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1,151 | -16,224 | -16,962 | -9,416 | 5,127 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2,153 | -657 | -4,991 | 2,194 | -1,172 |